Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors. 1988

R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
Epidemiology Program Office, Centers for Disease Control, Atlanta.

From April 8, 1982, through June 1984, 11 patients in a single hospital experienced 17 episodes of limb edema and discoloration after the intravenous (IV) administration of phenytoin sodium (Dilantin). One patient required a below-the-elbow amputation; all other patients recovered. No single drug lot was implicated. A case-control study was performed using three controls for each case; controls received IV infusions of phenytoin and were hospitalized close in time to the case patients. Compared with controls, patients with reactions were more often female and elderly and had underlying cardiovascular disease. Affected patients also received phenytoin through an IV catheter smaller than 20 gauge (50% vs 6%), at a rate greater than 25 mg/min (63% vs 19%), and in two or more IV infusions of phenytoin given "IV push" at the same site (81% vs 24%). High-risk patients require careful monitoring and stricter guidelines for the IV administration of phenytoin.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D002404 Catheterization Use or insertion of a tubular device into a duct, blood vessel, hollow organ, or body cavity for injecting or withdrawing fluids for diagnostic or therapeutic purposes. It differs from INTUBATION in that the tube here is used to restore or maintain patency in obstructions. Cannulation,Cannulations,Catheterizations
D003240 Connective Tissue Diseases A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides. Connective Tissue Disease,Disease, Connective Tissue,Diseases, Connective Tissue
D004487 Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE. Dropsy,Hydrops,Anasarca
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
August 1989, Archives of internal medicine,
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
March 1998, Deutsche medizinische Wochenschrift (1946),
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
September 1988, Drug intelligence & clinical pharmacy,
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
November 1994, Acta paediatrica (Oslo, Norway : 1992),
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
July 1995, Cancer,
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
February 1991, Annals of emergency medicine,
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
November 1984, The New England journal of medicine,
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
August 2011, Archives of disease in childhood,
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
February 2007, Vascular medicine (London, England),
R F Spengler, and J B Arrowsmith, and D J Kilarski, and C Buchanan, and L Von Behren, and D R Graham
January 1986, Developmental pharmacology and therapeutics,
Copied contents to your clipboard!